RxDoctor Payments Data

Lynn Cronin, MD

Cardiovascular Disease · Norfolk, VANPI 1194716621

Payments from drug & device makers

$794in general payments, 2019–2025

Across 11 payments — averaging $72.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Analog Devices Inc.$360
  • Irhythm Technologies, Inc.$175
  • Johnson & Johnson$156
  • Novartis$26
  • Bracco Diagnostics Inc.$25
  • Lantheus Medical Imaging, Inc.$19
  • plus $33 from 2 others

What the payments were for

  • Consulting fees$36045%
  • Food & beverage$43455%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$794 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$22,775
Medicare patients
203
Services billed
284

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban466$530,143
XareltoRivaroxaban286$293,346
EntrestoSacubitril/Valsartan111$135,904
JardianceEmpagliflozin50$46,426
FarxigaDapagliflozin Propanediol26$30,167
Repatha SureclickEvolocumab19$10,014
Metoprolol Succinate324$9,039
Atorvastatin Calcium246$4,084
Losartan Potassium221$3,978
Bisoprolol Fumarate65$3,646
Flecainide Acetate58$3,268
Carvedilol177$2,924
Ranolazine ErRanolazine37$2,731
Bumetanide47$2,504
Diltiazem 24hr Er (Cd)Diltiazem Hcl75$2,329

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$156$293,346286 claims
NovartisEntresto$26$135,904111 claims
Boehringer IngelheimJardiance$16$46,42650 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Norfolk

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →